Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATIC-2: LTOWB vs Component Therapy and TXA vs Placebo in Pediatric Trauma
NCT06070350Phase 3Recruiting
- Start
- Nov 2024
- Primary completion
- Jun 2028
- Modality
- Small Molecules, Tissue Cells
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tranexamic acid and low-titer group O whole blood in hemorrhagic shock and traumatic injury (4 arms). Primary endpoint: All-cause mortality at 24 hours. Started Nov 2024; status: recruiting.
02
Drugs
tranexamic acidlow-titer group O whole blood
03
Conditions
hemorrhagic shocktraumatic injury
Beyond the preview
Go deeper on NCT06070350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06070350.